BioSpace News Archive

Novo Warns EU of GLP-1 Drug Shortages, Expands Production at French Site

Novo Nordisk is diverting manufacturing capacity away from its older GLP-1 drug Victoza in order to cater to sky-high Ozempic demand.

November 27, 2023
·
2 min read
·
Tristan Manalac
Drug Development

GSK Builds Case for Blenrep’s Comeback with Promising Phase III Data

A year after exiting the U.S. market, GSK is setting the stage for the antibody-drug conjugate’s possible return in relapsed/refractory multiple myeloma.

November 27, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD

New data show the biologic significantly reduced exacerbations in chronic obstructive pulmonary disease, confirming positive results from an earlier trial.

November 27, 2023
·
2 min read
·
Tyler Patchen
Drug Development

89bio Unveils Bullish Long-Term Data for NASH Candidate

Pegozafermin showed statistically significant improvements in treating patients with nonalcoholic steatohepatitis, notching a win in the race to get the first treatment to market for the condition.

November 27, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Xenon Forging Ahead in MDD Despite Mid-stage Flop

While XEN1101 failed to hit the primary endpoint in a Phase II trial, the Canadian company is “actively exploring” further development of the program based on the totality of the data.

November 27, 2023
·
2 min read
·
Connor Lynch
Innate Pharma to Host Virtual KOL Event on Lacutamab

Innate Pharma SA announced that it will host a virtual KOL event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma and peripheral T cell lymphoma, on Tuesday, December 12, 2023, at 7:00AM PST.

November 27, 2023
·
7 min read
Drug Development

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

The second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial has shown that Dupixent significantly reduced exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.

November 27, 2023
·
19 min read
Drug Development

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent significantly reduced exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial.

November 27, 2023
·
26 min read
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

AB Science SA announces that a new clinical development program for masitinib in sickle cell disease is among the 19 winning projects to be funded under the sixth call for “Hospital-University Research in Health” projects, which is part of the Future Investments Program.

November 27, 2023
·
7 min read
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer

Hemogenyx Pharmaceuticals plc is pleased to announce that its Chimeric Bait Receptor platform can potentially be used in the treatment of cancers, in addition to the viral diseases extensively reported by the Company to date.

November 27, 2023
·
4 min read